News & Events 14 Oct 2024 Indian drug regulator recommends Wockhardt’s Miqnaf for treatment of CABP 11 Oct 2024 Wockhardt gets favourable recommendation from CDSCO for antibiotic for CABP 08 Oct 2024 USFDA grants fast track designation to Wockhardt novel antibiotic WCK 6777 07 Oct 2024 Wockhardt’s once-a-day antibiotic drug ‘WCK 6777’ successfully concludes Phase I study 07 Oct 2024 WCK 6777 passes trials; FDA grants fast track status to antibiotic for complicated UTIs 23 Sept 2024 Wockhardt’s Antibiotic Zaynich To Be Available In India At 80% Discount To US Price 20 Sept 2024 Wockhardt targets global launch of new meningitis drug with $6 bn market potential by 2026 19 Sept 2024 Wockhardt’s investigational drug, Zaynich demonstrates its ability to manage complex infections 16 Sept 2024 Wockhardt clinches BIRAC innovator award for novel antibiotic 03 Sep 2024 CDSCO Panel approves Wockhardt’s Protocol Amendment proposal for antimicrobial drug cefepime plus zidebactam 1 Jul 2024 US body Clinical and Laboratory Standards Institute (CLSI) awards high susceptibility breakpoints to Zaynich (Zidebactam/Cefepime- WCK 5222) 30 Jun 2024 City pharma’s new antibiotic to combat superbugs by year-end 29 Jun 2024 Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26 28 Jun 2024 Wockhardt claims breakthrough in drug-resistant infection in cancer patients with experimental drug Zaynich; US body awards highest susceptibility to the antibiotic 11 Mar 2024 Wockhardt announces success of antibiotic to treat drug-resistant infection 12 Jan 2024 Wockhardt has more antibiotics in the pipeline: Dr Habil Khorakiwala 14 Dec 2023 An antibiotics pipeline holds out promise for Wockhardt 11 Dec 2023 Wockhardt completes Phase 3 pneumonia study of macrolide antibiotic Nafithromycin WCK 4873 July 9, 2023 Wockhardt charting a recovery riding on a promising new antibiotic June 10, 2023 Engaging the pharmaceutical industry in joint efforts to tackle antimicrobial resistance February 21, 2023 A game-changer: India’s under-trial drug shows promise against hospital superbugs February 12, 2023 Under-trial antibiotic use saves minor thalassemia patient’s life November 13, 2022 Desi superbug antibiotic under trial saves Nepalese August 16, 2022 Wockhardt initiates phase-III clinical study of new antibiotic candidate March 16, 2022 National Institutes of Health (NIH), USA to conduct human Phase 1 trial of Wockhardt’s novel once-a-day MDR Gram-negative antibiotic WCK 6777 August 26, 2021 Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin January 16, 2021 India’s first new discovery antibiotics from Wockhardt granted Indian regulatory approval
